Login to Your Account



Other News To Note


Wednesday, January 25, 2012

• Depomed Inc., of Menlo Park, Calif., said it received a Paragraph IV certification notice of an abbreviated new drug application filed by Actavis Group, of Zug, Switzerland, seeking approval for a generic version of Gralise (gabapentin) 300-mg and 600-mg tablets. Actavis' notice alleges that Depomed's six U.S. patents for Gralise will not be infringed by Actavis' proposed product, or alleges that they are invalid and/or are unenforceable.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription